Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zeo ScientifiXZEOX +1.68%50 Receivables Turnover is 15.23 as of Apr. 2026. GuruFocus rates ZEOX with a GF Score™ of 50/100 and a GF Value™ of $2.66 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 841 Biotechnology companies, Zeo ScientifiX ranks better than 96.55% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Zeo ScientifiX's Revenue for the
three
months ended in Apr. 2026 was $2.58 Mil. Zeo ScientifiX's average Accounts Receivable for the
three
months ended in Apr. 2026 was $0.17 Mil.
Hence, Zeo ScientifiX's Receivables Turnover for the
three
months ended in Apr. 2026 was 15.23.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Zeo ScientifiX Receivables Turnover Related Terms
Zeo ScientifiX Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Zeo ScientifiX's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZEOX vs JUNS, HOOK, LEXX: Receivables Turnover Comparison
For the Biotechnology subindustry, Zeo ScientifiX's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeo ScientifiX Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeo ScientifiX (ZEOX) has a Receivables Turnover of 15.23 as of Apr. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zeo ScientifiX and its competitors. According to the industry distribution chart, Zeo ScientifiX ranks #29 out of 841 companies in the Biotechnology industry, placing it in the top 3.4%.
Is Zeo ScientifiX's Receivables Turnover too high?
Zeo ScientifiX's current Receivables Turnover is 15.23. The Biotechnology industry median Receivables Turnover is 5.29. Zeo ScientifiX's value of 15.23 is 187.9% above this industry median. Based on the distribution chart, Zeo ScientifiX ranks #29 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zeo ScientifiX has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zeo ScientifiX's Receivables Turnover compare to JUNS and HOOK?
According to the Biotechnology industry distribution chart, Zeo ScientifiX ranks #29 out of 841 companies for Receivables Turnover. This places Zeo ScientifiX in the top 3% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. Zeo ScientifiX's value of 15.23 is 187.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zeo ScientifiX's current Receivables Turnover of 15.23 is 187.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Zeo ScientifiX and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zeo ScientifiX's current Receivables Turnover is 15.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeo ScientifiX stock overvalued right now?
Based on GuruFocus' analysis, Zeo ScientifiX (ZEOX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.66, compared to a current price of $1.82 — trading 31.6% below its estimated fair value. The current Receivables Turnover is 15.23 and 187.9% above the Biotechnology industry median of 5.29. Zeo ScientifiX's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Zeo ScientifiX (ZEOX), the current Receivables Turnover is 15.23 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zeo ScientifiX (ZEOX) Overvalued in 2026?
Based on GuruFocus' analysis, Zeo ScientifiX stock appears to be undervalued.
The current stock price of $1.82 is trading 31.6% below its estimated GF Value™ of $2.66.
GuruFocus considers Zeo ScientifiX to be Possible Value Trap.
Key valuation signals for ZEOX:
Receivables Turnover: 15.23
GF Value™: $2.66 vs. price of $1.82 (31.6% below fair value)
Industry Position: 187.9% above the Biotechnology median (#29 of 841)
No single metric tells the full story. See the ZEOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
50GF Score
Get the complete analysis for ZEOX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZEOX has been successfully added to your 
